Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TNRC6B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TNRC6B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TNRC6B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TNRC6B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TNRC6B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TNRC6B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TNRC6B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TNRC6B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TNRC6B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TNRC6B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0060966 | Colorectum | MSS | regulation of gene silencing by RNA | 19/3467 | 53/18723 | 2.14e-03 | 1.80e-02 | 19 |
GO:2000637 | Colorectum | MSS | positive regulation of gene silencing by miRNA | 12/3467 | 30/18723 | 5.00e-03 | 3.46e-02 | 12 |
GO:0060148 | Colorectum | MSS | positive regulation of posttranscriptional gene silencing | 12/3467 | 31/18723 | 6.80e-03 | 4.39e-02 | 12 |
GO:00064173 | Colorectum | MSI-H | regulation of translation | 73/1319 | 468/18723 | 9.89e-11 | 1.66e-08 | 73 |
GO:00098963 | Colorectum | MSI-H | positive regulation of catabolic process | 64/1319 | 492/18723 | 1.39e-06 | 9.16e-05 | 64 |
GO:19033113 | Colorectum | MSI-H | regulation of mRNA metabolic process | 43/1319 | 288/18723 | 2.31e-06 | 1.40e-04 | 43 |
GO:00313313 | Colorectum | MSI-H | positive regulation of cellular catabolic process | 56/1319 | 427/18723 | 4.89e-06 | 2.54e-04 | 56 |
GO:00064013 | Colorectum | MSI-H | RNA catabolic process | 36/1319 | 278/18723 | 2.95e-04 | 7.25e-03 | 36 |
GO:00442703 | Colorectum | MSI-H | cellular nitrogen compound catabolic process | 52/1319 | 451/18723 | 3.09e-04 | 7.50e-03 | 52 |
GO:00064023 | Colorectum | MSI-H | mRNA catabolic process | 31/1319 | 232/18723 | 4.39e-04 | 9.45e-03 | 31 |
GO:00346553 | Colorectum | MSI-H | nucleobase-containing compound catabolic process | 47/1319 | 407/18723 | 5.69e-04 | 1.14e-02 | 47 |
GO:00467003 | Colorectum | MSI-H | heterocycle catabolic process | 50/1319 | 445/18723 | 7.21e-04 | 1.37e-02 | 50 |
GO:00434873 | Colorectum | MSI-H | regulation of RNA stability | 24/1319 | 170/18723 | 8.57e-04 | 1.55e-02 | 24 |
GO:00434883 | Colorectum | MSI-H | regulation of mRNA stability | 22/1319 | 158/18723 | 1.65e-03 | 2.44e-02 | 22 |
GO:00194393 | Colorectum | MSI-H | aromatic compound catabolic process | 50/1319 | 467/18723 | 2.04e-03 | 2.85e-02 | 50 |
GO:00601472 | Colorectum | MSI-H | regulation of posttranscriptional gene silencing | 10/1319 | 52/18723 | 3.03e-03 | 3.80e-02 | 10 |
GO:00610133 | Colorectum | MSI-H | regulation of mRNA catabolic process | 22/1319 | 166/18723 | 3.09e-03 | 3.87e-02 | 22 |
GO:00609661 | Colorectum | MSI-H | regulation of gene silencing by RNA | 10/1319 | 53/18723 | 3.50e-03 | 4.18e-02 | 10 |
GO:19013613 | Colorectum | MSI-H | organic cyclic compound catabolic process | 51/1319 | 495/18723 | 4.07e-03 | 4.67e-02 | 51 |
GO:20006371 | Colorectum | MSI-H | positive regulation of gene silencing by miRNA | 7/1319 | 30/18723 | 4.10e-03 | 4.67e-02 | 7 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNRC6B | SNV | Missense_Mutation | | c.4778G>T | p.Arg1593Met | p.R1593M | Q9UPQ9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
TNRC6B | SNV | Missense_Mutation | | c.872N>T | p.Asp291Val | p.D291V | Q9UPQ9 | protein_coding | deleterious(0.01) | possibly_damaging(0.522) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNRC6B | SNV | Missense_Mutation | | c.1277N>T | p.Gly426Val | p.G426V | Q9UPQ9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
TNRC6B | SNV | Missense_Mutation | | c.4130N>T | p.Ser1377Phe | p.S1377F | Q9UPQ9 | protein_coding | tolerated(0.48) | probably_damaging(0.988) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
TNRC6B | SNV | Missense_Mutation | novel | c.4237N>A | p.Glu1413Lys | p.E1413K | Q9UPQ9 | protein_coding | deleterious(0) | benign(0.036) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs772135186 | c.1769N>A | p.Arg590His | p.R590H | Q9UPQ9 | protein_coding | deleterious(0.05) | probably_damaging(0.984) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs267606255 | c.79N>A | p.Glu27Lys | p.E27K | Q9UPQ9 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs267606255 | c.79N>A | p.Glu27Lys | p.E27K | Q9UPQ9 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-B6-A1KI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | | c.769N>A | p.Gly257Arg | p.G257R | Q9UPQ9 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TNRC6B | SNV | Missense_Mutation | rs778520882 | c.5N>A | p.Arg2Lys | p.R2K | Q9UPQ9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.267) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |